Author Interviews, Duke, Leukemia, Nature / 12.12.2025
Duke and Duke-NUS Scientists Identify Metabolic Vulnerability in AML Using New Computational Approach
MedicalResearch.com Interview with:
[caption id="attachment_71759" align="alignleft" width="200"]
Dr. Matthew Hirschey[/caption]
Matthew Hirschey Ph.D.
Associate Professor of Medicine
Associate Professor of Cell Biology
Associate Professor in Pharmacology and Cancer Biology
Member of the Duke Cancer Institute
Member of Sarah W. Stedman Nutrition and Metabolism Center
Hirschey Lab in the Duke Molecular Physiology Institute,
Duke University
MedicalResearch.com: What is the background for this study? Would you briefly describe AML and why new therapeutic approaches are needed?
Response: Acute myeloid leukemia (AML) is an aggressive blood cancer that begins in the bone marrow and progresses rapidly. While recent advances, particularly the BCL-2 inhibitor venetoclax combined with other agents, have improved outcomes for some patients, many still relapse or don't respond to treatment. The five-year survival rate remains below 30% overall, highlighting an urgent need for new therapeutic strategies.
We know that cancer cells rewire their metabolism to fuel rapid growth, and the mitochondria (the cell's powerhouses) play a central role. However, understanding exactly how different metabolic pathways connect and depend on each other has been challenging. We wanted to develop better tools to map these connections and identify new vulnerabilities we could potentially target.
Dr. Matthew Hirschey[/caption]
Matthew Hirschey Ph.D.
Associate Professor of Medicine
Associate Professor of Cell Biology
Associate Professor in Pharmacology and Cancer Biology
Member of the Duke Cancer Institute
Member of Sarah W. Stedman Nutrition and Metabolism Center
Hirschey Lab in the Duke Molecular Physiology Institute,
Duke University
MedicalResearch.com: What is the background for this study? Would you briefly describe AML and why new therapeutic approaches are needed?
Response: Acute myeloid leukemia (AML) is an aggressive blood cancer that begins in the bone marrow and progresses rapidly. While recent advances, particularly the BCL-2 inhibitor venetoclax combined with other agents, have improved outcomes for some patients, many still relapse or don't respond to treatment. The five-year survival rate remains below 30% overall, highlighting an urgent need for new therapeutic strategies.
We know that cancer cells rewire their metabolism to fuel rapid growth, and the mitochondria (the cell's powerhouses) play a central role. However, understanding exactly how different metabolic pathways connect and depend on each other has been challenging. We wanted to develop better tools to map these connections and identify new vulnerabilities we could potentially target.
Dr. Mosnaim[/caption]
Dr. Giselle Mosnaim MD MS FACAAI
Allergist
Division of Allergy and Immunology
Department of Medicine
Northshore University Health System
REMIX-1/-2 Investigator
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment.
The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
Dr. Serena Guo[/caption]
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
[caption id="attachment_71231" align="alignleft" width="125"]
Dr. Hao Dai[/caption]
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Dr. Del Pozo Cruz[/caption]
MedicalResearch.com Interview with:
Borja del Pozo Cruz, PhD
Department of Sport Sciences
Faculty of Medicine, Health, and Sport Sciences
Universidad Europea de Madrid
MedicalResearch.com: What is the background for this study?
Response: We now have consistent evidence that taking around 7,000 to 10,000 steps per day is associated with substantially lower risks of death and cardiovascular disease. However, much less is known about how those steps are accumulated throughout the day. This question is particularly relevant for people who are mostly inactive, as their steps are often of lower intensity and accumulated in short, fragmented bouts. Understanding whether different step accumulation patterns have distinct health effects in this group is essential to refine physical activity recommendations and make them more inclusive.
Shemyia Smith[/caption]
Shemyia Smith, MBS
Department of Medical Education
Geisinger College of Health Sciences
Scranton, PA 18509
MedicalResearch.com: What is the background for this study?
Response: Over the past several years, legal marijuana (also known as cannabis) use has substantially increased in many states and countries. Alongside this, more patients visit the emergency room and specialist with severe recurring nausea, vomiting, and abdominal pain. Often, this may be misdiagnosed since these symptoms are now known as Cannabinoid Hyperemesis Syndrome (CHS). Although CHS is now widely known, there is still a lot of uncertainty among clinicians about how to diagnose it confidently and manage it effectively.
Dr. Massimiliano[/caption]
MedicalResearch.com Interview with:
Massimiliano Orri, PhD
Assistant Professor in the Department of Psychiatry
McGill University
Principal Investigator at the Douglas Research Centre
within the McGill Group for Suicide Studies.
MedicalResearch.com: What is the background for this study? What types of medical conditions were associated with the early cannabis use?
Response: We already know that cannabis use can be linked to both mental and physical health problems. But what about problems severe enough to require medical attention? In this study, we wanted to see whether young adults who had used cannabis during their teenage years were more likely to seek medical care for mental or physical health issues. Using medical service data allows us to look at more serious cases - those that required professional attention and were diagnosed by healthcare providers. It also helps us understand the broader impact of early cannabis use on the healthcare system
Dr. Dehghani[/caption]
MedicalResearch.com Interview with:
Ali Dehghani, DO
Department of Medicine
University Hospitals Cleveland Medical Center / Case Western Reserve University
Presenting Author, IDWeek 2025
MedicalResearch.com: What is the background for this study?
Response: Shingles (herpes zoster) is caused by reactivation of the varicella-zoster virus, which can inflame blood vessels and the nervous system. Evidence over the past decade has linked shingles to higher risks of heart attack, stroke, and dementia—but it was unclear whether the shingles vaccine might lessen those long-term effects.
[caption id="attachment_71061" align="aligncenter" width="500"]
Clubfoot
Dr. Jiyoung Ahn[/caption]
MedicalResearch.com Interview with:
Jiyoung Ahn, PhD